Blue Owl Capital Holdings LP Acquires 115,000 Shares of Immuneering Corporation $IMRX

Blue Owl Capital Holdings LP lifted its position in shares of Immuneering Corporation (NASDAQ:IMRX) by 20.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 665,000 shares of the company’s stock after purchasing an additional 115,000 shares during the period. Immuneering accounts for approximately 0.3% of Blue Owl Capital Holdings LP’s investment portfolio, making the stock its 24th biggest holding. Blue Owl Capital Holdings LP’s holdings in Immuneering were worth $4,376,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in IMRX. Jane Street Group LLC acquired a new stake in Immuneering during the first quarter worth approximately $32,000. Geode Capital Management LLC boosted its holdings in shares of Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after purchasing an additional 4,458 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Immuneering in the 2nd quarter valued at $90,000. Bridgeway Capital Management LLC boosted its holdings in shares of Immuneering by 57.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after purchasing an additional 35,000 shares in the last quarter. Finally, Corient Private Wealth LLC acquired a new stake in shares of Immuneering in the 2nd quarter valued at $215,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Price Performance

Shares of NASDAQ:IMRX opened at $5.39 on Monday. The firm has a market cap of $348.73 million, a P/E ratio of -4.61 and a beta of 0.37. Immuneering Corporation has a 12-month low of $1.42 and a 12-month high of $10.08. The business has a fifty day simple moving average of $5.31 and a 200 day simple moving average of $5.65.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.09. As a group, equities research analysts expect that Immuneering Corporation will post -1.16 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on IMRX. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 target price on shares of Immuneering in a report on Tuesday, May 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Friday, March 27th. Wall Street Zen raised Immuneering from a “sell” rating to a “hold” rating in a report on Sunday, April 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Immuneering in a report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.